Patient Ineligibility as a Barrier to Participation in Clinical Trials

被引：3

作者：

Lawrence, Ryan ^{[1
]}

机构：

[1] Columbia Univ, Irving Med Ctr, New York, NY 10032 USA

来源：

AMERICAN JOURNAL OF BIOETHICS | 2023年 / 23卷 / 08期

关键词：

EXTENDED-RELEASE NALTREXONE; BUPRENORPHINE; XBOT;

D O I：

10.1080/15265161.2023.2217140

中图分类号：

B82 [伦理学（道德学）];

学科分类号：

摘要：

引用

页码：83 / 85

页数：3

共 9 条

[1] Do Clinicians Have a Duty to Participate in Pragmatic Clinical Trials? [J].

Garland, Andrew ;

Morain, Stephanie ;

Sugarman, Jeremy .

AMERICAN JOURNAL OF BIOETHICS, 2023, 23 (08) :22-32

[2] A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results [J].

Kennedy-Martin, Tessa ;

Curtis, Sarah ;

Faries, Douglas ;

Robinson, Susan ;

Johnston, Joseph .

TRIALS, 2015, 16

[3] Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial [J].

Lee, Joshua D. ;

Nunes, Edward V., Jr. ;

Novo, Patricia ;

Bachrach, Ken ;

Bailey, Genie L. ;

Bhatt, Snehal ;

Farkas, Sarah ;

Fishman, Marc ;

Gauthier, Phoebe ;

Hodgkins, Candace C. ;

King, Jacquie ;

Lindblad, Robert ;

Liu, David ;

Matthews, Abigail G. ;

May, Jeanine ;

Peavy, K. Michelle ;

Ross, Stephen ;

Salazar, Dagmar ;

Schkolnik, Paul ;

Shmueli-Blumberg, Dikla ;

Stablein, Don ;

Subramaniam, Geetha ;

Rotrosen, John .

LANCET, 2018, 391 (10118) :309-318

[4] NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale [J].

Lee, Joshua D. ;

Nunes, Edward V. ;

Novo, Patricia ;

Bailey, Genie L. ;

Brigham, Gregory S. ;

Cohen, Allan J. ;

Fishman, Marc ;

Ling, Walter ;

Lindblad, Robert ;

Shmueli-Blumberg, Dikla ;

Stablein, Don ;

May, Jeanine ;

Salazar, Dagmar ;

Liu, David ;

Rotrosen, John .

CONTEMPORARY CLINICAL TRIALS, 2016, 50 :253-264

[5] Effectiveness of antipsychotic drugs in patients with chronic schizophrenia [J].

Lieberman, JA ;

Stroup, TS ;

McEvoy, JP ;

Swartz, MS ;

Rosenheck, RA ;

Perkins, DO ;

Keefe, RSE ;

Davis, SM ;

Davis, CE ;

Lebowitz, BD ;

Severe, J ;

Hsiao, JK .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (12) :1209-1223

[6] Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design [J].

Rush, AJ ;

Fava, M ;

Wisniewski, SR ;

Lavori, PW ;

Trivedi, MH ;

Sackeim, HA ;

Thase, ME ;

Nierenberg, AA ;

Quitkin, FM ;

Kashner, TM ;

Kupfer, DJ ;

Rosenbaum, JF ;

Alpert, J ;

Stewart, JW ;

McGrath, PJ ;

Biggs, MM ;

Shores-Wilson, K ;

Lebowitz, BD ;

Ritz, L ;

Niederehe, G .

CONTROLLED CLINICAL TRIALS, 2004, 25 (01) :119-142

[7]

The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1979, The Belmont Report.

[8]

Thorpe KE, 2009, J CLIN EPIDEMIOL, V62, P464, DOI [10.1016/j.jclinepi.2008.12.011, 10.1503/cmaj.090523]

[9] Eligibility criteria of randomized controlled trials published in high-impact general medical journals - A systematic sampling review [J].

Van Spall, Harriette G. C. ;

Toren, Andrew ;

Kiss, Alex ;

Fowler, Robert A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (11) :1233-1240

← 1 →